Roche touts Swiss-led R&D unit after years in Genentech's shadow

Zurich

ROCHE is touting prospective new drugs from its long-underperforming Swiss-led research unit after years of leaning on its California-based Genentech arm to restock its medicine cabinet.

This year, the Swiss drugmaker - the top global spender in pharmaceutical research and development (R&D) - has been talking up several medicines being trialled by Roche Pharma Research & Early Development, or "pRED", as potential stars.